Clinical trial

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

NCT05800340

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-04-04

PhasePHASE2

Study timeline

Study start (actual)2023-04-04Date precision: day

Registry last updated2023-04-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

RET Driver Mutationunresolved

BRAF V600 Mutationunresolved

Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutationunresolved

MET Amplificationunresolved

MET Exon 14 Skipping Mutationunresolved

Interventions

ToripalimabBIOLOGICAL

Nab paclitaxelDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Guangdong Provincial People's Hospitallead sponsor

Shanghai Junshi Bioscience Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05800340 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.